Trials with impact on clinical management: first line.

Trials with impact on clinical management: first line.

Item
http://www.wikidata.org/entity/Q37643329
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.Bevacizumab in the treatment of ovarian cancer.Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.Emerging treatment options for management of malignant ascites in patients with ovarian cancer.Bevacizumab and ovarian cancerEpithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
P2860

Trials with impact on clinical management: first line.

Item
http://www.wikidata.org/entity/Q37643329
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trials with impact on clinical management: first line.
@en
Trials with impact on clinical management: first line.
@nl
type
label
Trials with impact on clinical management: first line.
@en
Trials with impact on clinical management: first line.
@nl
prefLabel
Trials with impact on clinical management: first line.
@en
Trials with impact on clinical management: first line.
@nl
P1433
P1476
P2093
P304
P31
P356
P478
P577
P698
P356
P1433
P1476
Trials with impact on clinical management: first line.
@en
P2093
P304
P31
P356
10.1111/IGC.0B013E3181C36EA0
P478
P577
P698